Evidence map›Paper›PMID 19156339›Full record

ReviewDer Urologe. Ausg. A2009

[Andrological testosterone replacement therapy].

U Paasch, H-J Glander, J-U Stolzenburg

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Der Urologe. Ausg. A, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

U PaaschWeiterbildungszentrum der European Academy of Andrology, Campus Leipzig, Klinik für Dermatologie, Venerologie und Allergologie der Universität Leipzig, Philipp-Rosenthal-Strasse 23-25, 04103 Leipzig. uwe.paasch@medizin.uni-leipzig.de
H-J Glander
J-U Stolzenburg
Leipzig University · DEUniversity Hospital Leipzig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Male hypogonadism is characterised by decreased testicular function, especially testosterone deficiency. Its prevalence increases with age but may be acquired in all stages of life if it is not inborn. The lack of testosterone results in typical clinical symptoms. However, only about 10% of the affected men currently receive adequate treatment. A variety of testosterone preparations are available to meet the main needs of treatment, including intramuscular, transcutaneous, sublingual, and oral forms. In patients with prostate cancer, breast cancer, polycythemia, severe heart failure, obstruction of the lower urinary tract, or untreated sleep apnoea, testosterone treatment must be avoided. Therefore, clinical and laboratory screening are essential along with a long-term substitution.

Indexed as

Hormone Replacement TherapyHumansHypogonadismMaleTestosteroneTestosterone

Identifiers

PMID19156339
OpenAlexW102063875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.